Shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX – Get Rating) have been given a consensus recommendation of “Moderate Buy” by the eight ratings firms that are covering the firm, Marketbeat Ratings reports. One research analyst has rated the stock with a sell rating and six have given a buy rating to the company. The average 12-month target price among brokerages that have issued a report on the stock in the last year is $33.57.
Several equities analysts recently weighed in on SNDX shares. JPMorgan Chase & Co. dropped their price target on shares of Syndax Pharmaceuticals from $41.00 to $36.00 and set an “overweight” rating on the stock in a research report on Tuesday, March 7th. Citigroup lifted their target price on shares of Syndax Pharmaceuticals from $29.00 to $32.00 and gave the stock a “buy” rating in a research report on Thursday, March 2nd. Stifel Nicolaus initiated coverage on shares of Syndax Pharmaceuticals in a research report on Monday, January 30th. They set a “buy” rating and a $37.00 target price on the stock. StockNews.com initiated coverage on shares of Syndax Pharmaceuticals in a research report on Thursday. They set a “sell” rating on the stock. Finally, The Goldman Sachs Group dropped their target price on shares of Syndax Pharmaceuticals from $39.00 to $34.00 and set a “buy” rating on the stock in a research report on Wednesday, March 1st.
Insider Activity at Syndax Pharmaceuticals
In other Syndax Pharmaceuticals news, Director Pierre Legault sold 24,000 shares of the business’s stock in a transaction on Thursday, January 12th. The stock was sold at an average price of $26.74, for a total value of $641,760.00. Following the sale, the director now directly owns 32,000 shares of the company’s stock, valued at $855,680. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. In other news, Director Pierre Legault sold 24,000 shares of Syndax Pharmaceuticals stock in a transaction that occurred on Thursday, January 12th. The shares were sold at an average price of $26.74, for a total value of $641,760.00. Following the completion of the sale, the director now directly owns 32,000 shares in the company, valued at $855,680. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Michael A. Metzger sold 5,959 shares of Syndax Pharmaceuticals stock in a transaction that occurred on Monday, February 6th. The stock was sold at an average price of $27.64, for a total transaction of $164,706.76. Following the completion of the sale, the chief executive officer now owns 17,659 shares of the company’s stock, valued at $488,094.76. The disclosure for this sale can be found here. Insiders have sold 160,667 shares of company stock worth $4,061,340 over the last ninety days. 6.30% of the stock is owned by corporate insiders.
Hedge Funds Weigh In On Syndax Pharmaceuticals
Syndax Pharmaceuticals Price Performance
NASDAQ:SNDX opened at $22.25 on Friday. The firm’s 50 day simple moving average is $25.56 and its 200 day simple moving average is $24.23. The company has a market cap of $1.52 billion, a PE ratio of -9.08 and a beta of 1.04. Syndax Pharmaceuticals has a one year low of $13.27 and a one year high of $29.86.
Syndax Pharmaceuticals (NASDAQ:SNDX – Get Rating) last issued its earnings results on Tuesday, February 28th. The company reported ($0.62) EPS for the quarter, beating the consensus estimate of ($0.64) by $0.02. Equities research analysts expect that Syndax Pharmaceuticals will post -3.04 EPS for the current year.
About Syndax Pharmaceuticals
Syndax Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company engaged in the development of cancer therapies. Its product candidates include SNDX-5613 and SNDX-6352. The company was founded by Richard A. Heyman, Eckard Weber, Peter Ordentlich, Ronald M. Evans and Michael Downes on October 11, 2005 and is headquartered in Waltham, MA.
- Get a free copy of the StockNews.com research report on Syndax Pharmaceuticals (SNDX)
- MarketBeat Week in Review – 3/13 – 3/17
- This Small Tech With Big Growth Prospects Is Nearing A Buy Point
- Don’t Chase FedEx Higher, Wait For The Pullback
- 3 Stocks For A Defensive Tech Portfolio
- Milk the Dividends on These 3 Cash Cows
Receive News & Ratings for Syndax Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syndax Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.